Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: One-year follow-up of an open-label study

José M. Ponseti, Jamal Azem, José M. Fort, Agustín Codina, J. Bruno Montoro, Manuel Armengol

Research output: Contribution to journalArticleResearchpeer-review

37 Citations (Scopus)

Abstract

Thirteen patients with myasthenia gravis, unresponsive to prednisone and cyclosporin after thymectomy, received KF506 (tacrolimus) for 12 months, at starting doses of 0.1 mg/kg per day b.i.d. and then adjusted to achieve plasma concentrations between 7 and 8 ng/mL. The doses of prednisone were progressively reduced and finally discontinued. Anti-acetylcholine antibodies and myasthenia gravis score for disease severity decreased significantly and muscular strength increased by 37%. All patients achieved pharmacological remission, 11 were asymptomatic and two had minimal weakness of eyelid closure. Tacrolimus was well tolerated and appears a suitable approach after unsuccessful treatment with conventional immunosuppressants in patients with disabling myasthenia. © 2004 Elsevier B.V. All rights reserved.
Original languageEnglish
Pages (from-to)187-190
JournalClinical Neurology and Neurosurgery
Volume107
DOIs
Publication statusPublished - 1 Jan 2005

Keywords

  • Cyclosporin
  • Myasthenia gravis
  • Prednisone
  • Tacrolimus

Fingerprint

Dive into the research topics of 'Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: One-year follow-up of an open-label study'. Together they form a unique fingerprint.

Cite this